Mednet Logo

How do you risk stratify patients with MRI guided prostate biopsies?

This may impact decisions on brachytherapy boost and/or use of ADT since MRI-guided samples may skew patients into the unfavorable risk category
4 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Rutgers Cancer Institute of New Jersey
Answered on

If the patient has had standard template biopsies and targeted biopsies, I only consider that standard biopsies in the quantification of the proportion of cores involved since the data used to derive the prognostic significance of this feature was based on standard template biopsies not targeted cor...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Nuvance Health
Answered on

I'm similar to Dr. @Dr. First Last -- the studies that established the number of cores as risk factors looked at biopsies with 8-10 cores for the most part. In the setting where there are both MRI-guided and standard template biopsies, I divide those out when making decisions on risk stratification ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Allan Blair Cancer Centre
Answered on

I use the systematic biopsy to determine the core % positivity, I use the highest grade to determine the Gleason score as nodules will sometimes show higher grade disease which oncologically would be silly to ignore, and I use PSA at the time of biopsy. Of course, each patient is individual but this...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Via Christi Health
Answered on

Correct me if I am wrong, but there are 3 decisions that we make when we are stratifying patients into risk groups; 1. Should we add pelvic RT, 2. should we add ADT, 3.and using this information to show patients how poor surgery is for controlling their cancer(MSKCC & CAPRA). We have a large primary...

Join for free or sign in to see the full answer